Considering that PD-1/PD-L1 interaction can suppress anti-tumor immunity (40), we hypothesized that combination treatment with cytokine mRNA triplet and PD-1/PD-L1 blockade would enhance the anti-tumor efficacy. This evidence concerns the gene CD274 and neoplasm.